Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).
Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei SB, Samaras P, Mey U, Driessen C; Swiss Group for Clinical Cancer Research SAKK. Hitz F, et al. Among authors: kraus m. Blood Cancer J. 2019 Aug 27;9(9):70. doi: 10.1038/s41408-019-0228-2. Blood Cancer J. 2019. PMID: 31455773 Free PMC article. Clinical Trial.
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M, Bader J, Geurink PP, Weyburne ES, Mirabella AC, Silzle T, Shabaneh TB, van der Linden WA, de Bruin G, Haile SR, van Rooden E, Appenzeller C, Li N, Kisselev AF, Overkleeft H, Driessen C. Kraus M, et al. Haematologica. 2015 Oct;100(10):1350-60. doi: 10.3324/haematol.2014.109421. Epub 2015 Jun 11. Haematologica. 2015. PMID: 26069288 Free PMC article.
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C. Kraus J, et al. Among authors: kraus m. Cancer Chemother Pharmacol. 2015 Aug;76(2):383-96. doi: 10.1007/s00280-015-2801-0. Epub 2015 Jun 23. Cancer Chemother Pharmacol. 2015. PMID: 26099967 Free PMC article.
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft HS, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey UJ. Driessen C, et al. Among authors: kraus m. Haematologica. 2016 Mar;101(3):346-55. doi: 10.3324/haematol.2015.135780. Epub 2015 Dec 11. Haematologica. 2016. PMID: 26659919 Free PMC article. Clinical Trial.
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.
Soriano GP, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N, Bader J, Everts B, den Dulk H, Overkleeft HS, Florea BI, Driessen C. Soriano GP, et al. Among authors: kraus m. Leukemia. 2016 Nov;30(11):2198-2207. doi: 10.1038/leu.2016.102. Epub 2016 Apr 27. Leukemia. 2016. PMID: 27118406 Free PMC article.
1,177 results